Cingulate added to Russell 3000E Index, extends CMO's employment trial period

Cingulate Inc. (NASDAQ: CING) disclosed in an 8-K filing that it has been added to the Russell 3000E® Index, as announced on July 2, 2026 from Kansas City, Kansas.¹

CEO Shane Schaffer said the inclusion underscores Cingulate's continued evolution as a public company.¹ He added that the company believes the inclusion will enhance visibility with institutional investors, expand market awareness, and position the company for long-term growth,¹ while noting the company is advancing CTx-1301, its lead ADHD product candidate, alongside its Precision Timed Release platform.¹

The filing describes the index itself, noting that Russell US Indexes serve as benchmarks for institutional investors, with a modular construction that allows tracking of market performance by segment or style.¹ The filing also notes that Russell Indexes are fully reconstituted each June and will be subject to semi-annual reconstitution starting in December 2026.¹

Separately, the 8-K disclosed a personnel matter under Item 5.02. On June 30, 2026, Cingulate Therapeutics LLC, described as a wholly owned subsidiary of Cingulate Inc., entered into an amendment to the employment agreement of Matthew N. Brams, Executive Vice President and Chief Medical Officer, effective January 1, 2026.¹ Under the amendment, the trial period for Brams' full-time employment was extended from June 30, 2026 to September 30, 2026.¹

Regarding CTx-1301, the filing states it is a once-daily, multi-core tablet using the PTR platform to deliver three precisely timed releases of active medication across the day, and is being evaluated for ADHD treatment under the FDA's 505(b)(2) pathway.¹